| Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 … AC Ford, A Wright-Hughes, SL Alderson, PL Ow, MJ Ridd, R Foy, ... The Lancet 402 (10414), 1773-1785, 2023 | 25 | 2023 |
| Understanding survival analysis in clinical trials J Emmerson, JM Brown Clinical Oncology 33 (1), 12-14, 2021 | 17 | 2021 |
| Prognostic significance of negative lymph node long axis in esophageal cancer: results from the randomized controlled UK MRC OE02 trial M Kloft, JE Ruisch, G Raghuram, J Emmerson, M Nankivell, ... Annals of surgery 277 (2), e320-e331, 2023 | 7 | 2023 |
| A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL … C Williams, J Emmerson, AD Beggs, N West, JA Bridgewater, J Graham, ... Journal of Clinical Oncology 40 (16_suppl), TPS3633-TPS3633, 2022 | 4 | 2022 |
| Recommendations for designing and analysing multi-arm non-inferiority trials: a review of methodology and current practice J Emmerson, S Todd, JM Brown Trials 22 (1), 417, 2021 | 3 | 2021 |
| Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and … B Grosser, J Emmerson, NG Reitsam, D Cunningham, M Nankivell, ... British Journal of Cancer 130 (3), 457-466, 2024 | 1 | 2024 |
| Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial T Munir, J Emmerson, A Hockaday, JB Oughton, D Howard, D Phillips, ... British Journal of Haematology 199 (5), 707-719, 2022 | 1 | 2022 |
| Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials DHW Liu, N Šefčovičová, J Emmerson, LN Spaans, Y Saito, G Hutchins, ... European Journal of Cancer 170, 140-148, 2022 | 1 | 2022 |
| COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study D Allsup, D Howard, J Emmerson, A Hockaday, A Rawstron, JB Oughton, ... | | 2021 |
| Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression … T Munir, D Howard, A Hockaday, J Oughton, J Emmerson, D Phillips, ... LEUKEMIA & LYMPHOMA 61, 209-210, 2020 | | 2020 |
| Recommendations for designing and analysing multi-arm non-inferiority trials J Emmerson, JM Brown, S Todd | | |
